The p53 tumor suppressor protein is widely known for its role as a sequence-specific transcription factor that regulates the expression of stress response genes. Here, we report the identification of LIMK2, which encodes a kinase that regulates actin dynamics through phosphorylation of cofilin, as a p53 target upregulated by DNA damage. Interestingly, the splice variant LIMK2b, but not LIMK2a, was induced in a p53-dependent manner through an intronic consensus p53-binding site. Depletion of LIMK2b leads to early exit of G2/M arrest after DNA damage, whereas its overexpression prolongs the arrest. These responses are recapitulated by ectopic expression of the active cofilin S3A mutant and the inactive cofilin S3D mutant, respectively, suggesting that LIMK2b may modulate G2/M arrest through cofilin phosphorylation. Furthermore, in support of its potential role as a tumor suppressor, LIMK2b was downregulated in esophageal and thyroid cancers, as well as in a number of established cancer cell lines, and its expression suppresses cancer cell migration. Taken together, our results unveil a novel pathway whereby LIMK2b, acting downstream of p53, ensures proper execution of checkpoint arrest by modulating the dynamics of actin polymerization.
Introduction
The tumor suppressor protein p53 has an important role in defense against various types of stress, which enables the genome integrity to be properly maintained (Lavin and Gueven, 2006) . The importance of p53 is further revealed by it being mutated in more than one-half of all human cancers, suggesting that loss of p53 function contributes to cancer development (Olivier et al., 2002) .
In unperturbed cells, the p53 protein is maintained at very low levels mainly because of Mdm2-mediated ubiquitination and degradation. When exposed to stresses, such as DNA damage, p53 is rapidly accumulated and stabilized by post-translational modifications (Toledo and Wahl, 2006; Olsson et al., 2007) . Events such as phosphorylation of the p53 N-terminal domain by ATM/ATR, CHK1 and CHK2 disrupt the interaction between p53 and Mdm2, resulting in p53 stabilization and activation (Bode and Dong, 2004; Lavin and Gueven, 2006) . As a transcription factor, p53 binds to a consensus sequence 5 0 -RRRCWWGYYY (N ¼ 0-13 bp) RRRCWWGYYY-3 0 in the promoter or intronic region of the target gene (Riley et al., 2008) . Through induction of different downstream targets, p53 promotes cell cycle arrest or apoptosis. The transcriptional targets p21, 14-3-3s and BTG2, for example, induce cell cycle arrest, whereas NOXA, Bax and PUMA promote apoptosis (Murray-Zmijewski et al., 2008) . Apart from these activities, accumulating evidence implicates the involvement of p53 in the regulation of cell migration and cytoskeleton reorganization, although the molecular basis of this has not been fully deciphered (Gade´a et al., 2002 (Gade´a et al., , 2007 Guo et al., 2003; Ongusaha et al., 2006) .
We have previously used a method of combining small interfering RNA (siRNA) knockdown of CHK1 with microarray analysis to identify genes whose expression was altered by DNA damage in a CHK1-dependent manner (Ou et al., 2007) . Here, we report the identification of a differentially expressed gene, LIMK2, a member of the LIMK serine/threonine protein kinase family that includes LIMK1. These kinases are structurally similar, that is, each has two LIM domains at the N-terminus followed by a PDZ domain and a kinase domain (Okano et al., 1995; Scott and Olson, 2007) . The activities of LIMK1 and LIMK2, respectively, are regulated by phosphorylation at Thr508 and Thr505 by the p21-activated kinase1/4 and the Rho-associated coilcontaining kinase (ROCK), a downstream effector of the Rho family of GTPases (Ohashi et al., 2000; Amano et al., 2001; Sumi et al., 2001) . These GTPases, including Rho, Cdc42 and Rac, have an important role in regulating actin reorganization at least in part by modulating the activity of the actin depolymerization factor, cofilin. LIMK1 and LIMK2 directly phosphorylate cofilin at Ser3. Phosphorylated cofilin loses its ability to bind and depolymerize actin, resulting in stabilization of actin filaments (Maekawa et al., 1999; Sumi et al., 1999) .
Studies on LIMK2 have revealed many faces of the kinase. It is widely expressed in all tissues and resides mainly in the cytoplasm of cells (Abe et al., 1996; Smolich et al., 1997) . The protein contains nuclear export and nuclear localization signals, and undergoes nucleocytoplasmic shuttling that is negatively regulated by protein kinase C (Goyal et al., 2005) . Functionally, LIMK2 acts downstream of the Cdc42 and Rho-ROCK pathways by inducing actin reorganization and actin stress fibers (Sumi et al., 1999) , and by mediating the effect of Transforming growth factor-b on reorganization of the cytoskeleton (Vardouli et al., 2005) . More recently, LIMK2 was reported to mediate the effect of ROCK in inducing the expression of cyclin A (Croft and Olson, 2006) .
Characterization of the LIMK2 gene has identified two alternative transcripts, LIMK2a and LIMK2b, which are derived from different promoters through alternative splicing of distinct first exons (Nomoto et al., 1999) . LIMK2a represents the full-length transcript, which encodes two complete N-terminal LIM domains, whereas LIMK2b encodes only one and a half LIM domains, with the first LIM domain partially replaced by an irrelevant sequence (Osada et al., 1996) . This replacement is unique to the LIMK2 gene and is well conserved between murine and human genes (Osada et al., 1996; Ikebe et al., 1997) . Whether LIMK2a and LIMK2b function differently remains unknown; however, the two proteins have distinct subcellular localizations (Osada et al., 1996) , the implications of which remain to be determined.
In this study, we provide evidence that LIMK2b, but not LIMK2a, is a novel target of p53. Through upregulation of LIMK2b, p53 may modulate the actin dynamics to ensure proper G2/M arrest and to suppress cytokinesis, thus preventing damaged cells from further cell cycle entry.
Results
Expression of LIMK2b, but not LIMK2a, is induced by DNA damage in a p53-dependent manner To identify genes whose expression was altered by DNA damage, we previously conducted microarray analyses of LNCaP cells with or without ionizing radiation (IR) treatment (Ou et al., 2007) . After analysis of the gene expression profiles, LIMK2, a known regulator of actin dynamics, was identified as a DNA damage-induced gene. Unlike BTG3 (Ou et al., 2007) , induction of LIMK2 was not CHK1-dependent, because siRNAmediated depletion of CHK1 did not abolish induction of LIMK2 by DNA damage (data not shown).
Human LIMK2 undergoes alternative splicing that generates two major transcripts and proteins, LIMK2a and LIMK2b, in multiple tissues and cell lines (Osada et al., 1996; Nomoto et al., 1999) . To determine which transcript was induced by DNA damage, RNA was examined by reverse transcription coupled with PCR using transcript-specific primers. Interestingly, LIMK2b, but not LIMK2a, was induced after treatment with IR, doxorubicin ( Figure 1a ) and ultraviolet irradiation (data not shown) in LNCaP and MCF7 cancer cells. Induction of LIMK2b, but not LIMK2a, was also observed in normal human fibroblast IMR90 after IR ( Figure 1b) .
As LIMK2b could be induced by DNA damage, we then scanned the gene for possible DNA damage response elements and found a consensus p53-binding site in intron 1 of LIMK2b that corresponds to intron 2 of LIMK2a. This site matches 17 of 20 bp in the consensus p53-binding site, with no spacer between the two half sites (see below and Figure 2a ). To investigate whether LIMK2b was regulated by p53 after DNA damage, endogenous p53 was downregulated by p53-targeting siRNA. As shown in Figure 1c , the knockdown of p53 reduced the induction of LIMK2b; however, this had no effect on the expression of LIMK2a. Concordantly, LIMK2b, but not LIMK2a protein, was upregulated by doxorubicin ( Figure 1d ) and ultraviolet (Supplementary Figure S1a) in control siRNA-transfected cells, and such increase was diminished in p53-depleted cells (Figure 1d ). In addition to LNCaP cells, damage-induced expression of LIMK2b was also observed in other wild-type (WT) p53 cells, such as MCF7 ( Figure 1e ) and HT1080 (data not shown); however, damage-induced expression of LIMK2b was not observed in MDA-MB-231 cells, which carry mutant p53, or in p53-null H1299 cells (Supplementary Figure S1b) . In some WT p53 cells, such as RKO, U2OS and HCT116, LIMK2b expression was not upregulated by doxorubicin (Supplementary Figure S1b and data not shown). Other damaging agents, such as IR, ultraviolet and camptothecin, also failed to induce LIMK2b in HCT116 cells (Supplementary Figure S1c ). The underlying cause of this is unclear.
LIMK2b is a direct target of p53
To determine whether the consensus p53-binding site (LIMK2-p53BS) in intron 1 of LIMK2b was functional, luciferase reporter assays were performed. A 610 bp intronic region encompassing the putative p53BS ( Figure 2a ) was cloned into a luciferase reporter plasmid upstream of the minimal SV40 promoter. As shown in Figure 2b , WT, but not mutant p53 R248W, activated the intronic sequence. Moreover, once the p53BS was mutated, p53 could no longer activate the reporter (Figure 2c ). Similar results were observed with a reporter carrying only the LIMK2-p53BS (Supplementary Figures S2a and b) , indicating that the p53BS alone could mediate transactivation by p53. A moderate increase by IR was also seen with the WT but not with the mutated reporter in U2OS cells carrying endogenous WT p53 (Supplementary Figure S2c) .
To determine whether p53 binds directly to the LIMK2-p53BS, we conducted an electrophoresis mobility shift assay using recombinant His-tagged p53 (Figure 2d ). In this assay, WT, but not mutated LIMK2-p53BS, competed with binding of the protein-DNA complex, which was upshifted by a p53-specific antibody showing its specificity. Furthermore, in chromatin immunoprecipitation assays, ectopically expressed WT p53, but not the R248W mutant, bound to the LIMK2b intron 1 region (Figure 2e ).
Concurrently, binding of endogenous p53 after induction by doxorubicin, ultraviolet and IR was also detected in this region (Figure 2f and Supplementary Figure S3) .
Taken together, these results indicate that the intronic LIMK2-p53BS sequence directly mediates the transactivation of LIMK2b by p53.
Overexpression of LIMK2 inhibits cell growth and increases ploidy As p53 is a major factor involved in the control of cell proliferation, to determine whether LIMK2b may mediate this activity, we performed a colony formation assay by expression of WT or kinase-defective (KD) LIMK2a or LIMK2b in HeLa (p53-compromised) cells ( Figure 3a ) and H1299 (p53-null) cells (Supplementary Figure S4) . Overexpression of WT LIMK2a or LIMK2b markedly reduced the number of colonies formed, whereas the KD mutants exhibited only a modest effect, suggesting that LIMK2, similar to p53, inhibits cell growth and that this activity is largely mediated through the kinase activity. As additional proof, we also conducted MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays with stable Tet-Off (d) Purified recombinant p53 bound the LIMK2-p53BS in vitro, which was competed by WT and not by mutated p53BS (mt). An electrophoresis mobility shift assay was performed using purified His-p53 and 32 P-labeled oligonucleotide derived from the LIMK2-p53BS as a probe. The p53-specific antibody, PAb421 (p53Ab), was added to supershift the p53/DNA complex. (e) Ectopically expressed WT p53, and not the R248W mutant, bound to the LIMK2b intron 1 in vivo. A chromatin immunoprecipitation (ChIP) assay was performed using the p53 antibody DO1 and lysates prepared from H1299 cells transfected with WT or mutant p53. Precipitated DNA was amplified by PCR using primers specific for LIMK2b intron 1 or the p21 promoter. Immunoblotting (IB) with the p53 antibody DO1 was also performed to determine the amounts of p53 in the lysate (Input) and in the immunoprecipitate (IP). (f) Endogenous p53 induced by doxorubicin (Dox) bound to the LIMK2b intron 1. A ChIP assay was conducted as in e, using lysates prepared from LNCaP cells treated with Dox. As a negative control, PCR using primers corresponding to the b-actin promoter was also performed.
LIMK2b links p53 to actin dynamics F-F Hsu et al that in addition to growth suppression, LIMK2b may also have a regulatory role in cell division. Multinucleation was also observed, although less pronounced, in LIMK2a-GFP cells in spite of an equivalent amount of expressed proteins (Figure 3d ).
Overexpression of LIMK2b in HeLa cells abrogates cytokinesis
To explore the role of LIMK2b in cell division, HeLa cells inducibly expressing GFP or LIMK2b-GFP were first synchronized in prometaphase with nocodazole, followed by time-lapse live-cell imaging after release. The GFP control cells successfully divided and reattached (Figure 4a ). By contrast, the LIMK2b-GFP cells failed to complete division and eventually either became disintegrated (Figure 4b , black arrowheads) or, in other cases, the incompletely separated daughter cells fused to become a single larger cell (Figure 4b , white arrowheads). When the centrosome number was examined by immunofluorescence microscopy using an antibody against g-tubulin, a significant proportion of LIMK2b-GFP cells were found to possess more than two centrosomes, whereas the majority of control GFP cells contained only two centrosomes (Figure 4c ).
To determine whether supernumerary centrosomes were the cause or the consequence of cytokinesis failure, the centrosome number in asynchronous interphase cells was also examined. These results indicated that cells with multiple centrosomes also appeared to have more than one nucleus (data not shown), suggesting that supernumerary centrosomes were most likely the consequence of failed cytokinesis. Cells expressing LIMK2a-GFP also displayed cytokinesis defects, although to a lesser extent (Supplementary Figure S5) .
As LIMK2 phosphorylates and inactivates cofilin (Arber et al., 1998; Sumi et al., 1999) , and the proper regulation of cofilin is required for cytokinesis (Gunsalus et al., 1995; Hotulainen et al., 2005) , we then determined whether cofilin phosphorylation was deregulated in LIMK2b-GFP cells. As reported previously (Amano et al., 2002) , phosphorylation of cofilin in control GFP cells increased in metaphase and then gradually decreased in telophase (Figure 4d ). By contrast, LIMK2b links p53 to actin dynamics F-F Hsu et al phospho-cofilin in LIMK2b-GFP cells persisted in the later phase of cell division, which was very likely the result of heightened LIMK2 activity in these cells (Figure 4d ). Collectively, these results indicate that LIMK2b, when induced, inhibits cytokinesis, and this is at least in part mediated through persistent phosphorylation and inactivation of cofilin in the later phase of mitosis.
LIMK2b promotes DNA damage-induced G2/M arrest Few studies have been conducted on the functions of LIMK2 other than regulation of cell morphology and LIMK2b links p53 to actin dynamics F-F Hsu et al cell motility. As LIMK2b was upregulated in a p53-dependent manner after DNA damage, we explored whether it may have also been involved in a DNA damage-induced checkpoint by an siRNA-mediated knockdown approach. MCF7 cells were transfected with LIMK2b-specific or control siRNA and then exposed to IR (Figure 5a ). When compared with control cells, which underwent proper G2 arrest, the LIMK2b-depleted cells exhibited early exit from the arrest (Figures 5b and c) . Interestingly, in contrast to LIMK2b depletion, ablation of LIMK2a did not compromise G2 arrest (Figures 5b and c) . This suggests that the distinct N-terminal domain of LIMK2b was responsible for its role in the G2/M checkpoint or that LIMK2b was having a dominant role in MCF7 cells.
In line with the defective G2 arrest, LIMK2b, but not LIMK2a knockdown cells, showed reduction in the accumulation of cyclin B1 and Cdc2-Tyr15 phosphorylation after IR (Figure 5d ).
To further confirm the involvement of LIMK2b in the G2/M block, ectopic expression of LIMK2b was performed. Transient expression of LIMK2b in HCT116 cells, a cell line in which LIMK2b is not normally induced by DNA damage, significantly augmented G2/M arrest after IR (Figures 5e and f) . This effect of LIMK2b did not require the presence of p53, as similar results were also observed in HCT116 p53
À/À cells (Supplementary Figure S6) . By contrast, expression of LIMK2b KD had no apparent effect (Figures 5e and f, and Supplementary Figure S6 ) despite comparable levels of expression (Figure 5e and Supplementary Figure S6a) . Consistently, levels of phospho-histone H3, an M-phase marker, was also much lower in IR-treated LIMK2b-expressing cells compared with those in control or LIMK2b KD-expressing cells (Figure 5g ).
Taken together, these results suggest that LIMK2b contributes to checkpoint regulation by promoting G2/M arrest after DNA damage, and this effect is very likely to require its kinase activity.
LIMK2b regulates the G2/M checkpoint through cofilin phosphorylation
Cofilin is by far the best-known substrate of LIMK2; however, its role in cell cycle checkpoint is undetermined. In light of the results presented above, we speculated that the G2/M checkpoint function of LIMK2b may be mediated through phosphorylation of cofilin. Indeed, cofilin phosphorylation was increased on IR in LNCaP cells (Figure 6a ), and this increase was abolished in LIMK2b-downregulated or p53-depleted cells (Figure 6b ). An increase in stress fibers, which was likely to be a result of phosphorylation and inactivation of cofilin, was also observed in MCF7 cells after IR (Supplementary Figure S7) . Furthermore, on ectopic expression of a phospho-mimicking cofilin mutant, S3D, the IR-induced G2 arrest was enhanced. Conversely, expression of a phospho-deficient mutant, S3A, accelerated exit from the arrest (Figures 6c, d and e) . Fluorescence-activated cell sorting (FACS) analysis following staining of the cells with anti-phospho-histone H3 antibody showed that S3D-transfected cells were arrested in G2 rather than trapped in the M-phase, exhibiting lower phospho-H3 staining compared with others at 12 h after irradiation (Figure 6f ). By contrast, the S3A-transfected cells, which showed early exit from the arrest, displayed higher phospho-H3 staining (Figure 6f ). As the cofilin mutants S3A and S3D recapitulated the effects of LIMK2b depletion and overexpression, respectively, we conclude that cofilin is the major downstream mediator of LIMK2b in G2/M checkpoint regulation. These results also highlight the involvement of actin dynamics in checkpoint control.
Differential regulation of LIMK2a and LIMK2b in human cancers
To explore the possible role of LIMK2b in human cancers, human cancer tissue arrays were analyzed for expression of LIMK2b as well as LIMK2a by quantitative PCR. These arrays contain reverse-transcribed cDNA prepared from normal and tumor tissues of various types and stages. Among the tissues analyzed, LIMK2 was found to be upregulated in some cancer tissues and downregulated in others (Supplementary Figure S8 and data not shown). Differential regulation of LIMK2a and LIMK2b was also observed. It is noted that expression of LIMK2b was markedly reduced, whereas LIMK2a expression was increased in gastroesophageal cancers (Supplementary Figure S8d) . Further analysis with an expanded sample size revealed that this most likely reflected the expression pattern in esophageal cancers (Figure 7a ). In cancers of stomach origin, LIMK2b was slightly upregulated, whereas LIMK2a was unchanged or slightly downregulated (data not shown). In addition to esophageal cancers, a marked reduction in the expression of both LIMK2a and LIMK2b was observed in carcinoma of the thyroid gland (Figure 7b ). Although the mechanism underlying the regulation remains unclear, these results imply a possible role for LIMK2b in negative regulation of tumor growth at least in esophageal and thyroid cancers.
Expression of LIMK2 in cancer cell lines was also examined. Significantly, in TT cells, a thyroid carcinoma cell line, LIMK2b, was not induced by DNA damage despite an intact p53 response (Figure 7c ). In these cells, induction of phospho-cofilin was barely noted after IR, but appeared to be normal after doxorubicin treatment (Figure 7d) , suggesting a damage type-specific effect. In addition, LIMK2b expression was downregulated in many cancer cell lines in which LIMK2a expression was largely unchanged (Figure 7e) . Furthermore, HeLa cells inducibly expressing LIMK2b-GFP exhibited reduced migration when compared with control GFP cells in a transwell assay. Interestingly, expression of LIMK2a-GFP did not impinge on or even slightly enhance cell migration (Figure 7f) , again showing the potentially distinct roles of LIMK2b and LIMK2a in tumor progression.
LIMK2b links p53 to actin dynamics F-F Hsu et al Overexpression of the cofilin Ser3-to-Asp (S3D) mutant promoted the IR-induced G2/M block, whereas the Ser3-to-Ala (S3A) mutant ameliorated the arrest. FACS analysis was performed on HCT116 cells ectopically expressing WT cofilin, the S3D mutant or the S3A mutant with or without X-ray irradiation (8 Gy). Expression of HA-tagged cofilin was assessed by western blotting and is shown in d. The extent of the G2 arrest, represented by G2/G1 ratios, was derived from three independent experiments and is shown in e. The percentage of cells in M-phase, represented by histone H3 Ser10 phosphorylation (H3-S10-P), at 0 and 12 h after IR is depicted in f. *Po0.05; **Po0.01. LIMK2b links p53 to actin dynamics F-F Hsu et al
Discussion
In this study, we have shown that LIMK2b is a direct transcriptional target of p53. LIMK2b is induced after DNA damage with kinetics similar to that of p21, a wellknown p53 target. We also provide evidence that LIMK2b has a role in promoting the G2/M DNAdamage checkpoint, and negatively regulates cytokinesis downstream of p53 on stress.
Selective activation of the LIMK2b but not the LIMK2a promoter As expression of LIMK2a and LIMK2b uses distinct promoters, one explanation would be that the upstream LIMK2a promoter is somehow inaccessible to p53, which we think is less likely because transcription factors often act from a distance. Alternatively, it is possible that a cis-element in the LIMK2b promoter, which is not present in the LIMK2a promoter,
LIMK2b links p53 to actin dynamics F-F Hsu et al cooperates with the intronic p53 element in response to stress signals. A plausible candidate that fits this criterion is the RORa1-binding site in the positive regulatory region of the LIMK2b promoter (Nomoto et al., 1999) . In support, RORa mRNA is often downregulated in tumor cell lines and cancers (Zhu et al., 2006; Lu et al., 2007; Jetten 2009) , and its expression is upregulated by a variety of genotoxic stresses (Zhu et al., 2006) . Whether this latter function also includes coactivation with p53, for example, in the transactivation of LIMK2b, remains to be determined. The functional implications of such differential regulation are intriguing. The LIMK2b protein contains a partially disrupted LIM domain (Figure 3a) , which led us to speculate that LIMK2b might competitively and/ or negatively regulate the function of LIMK2a on its upregulation by DNA damage. However, LIMK2a and LIMK2b were equally active in phosphorylating cofilin in vitro, and coexpression of KD LIMK2b did not seem to affect the kinase activity of immunoprecipitated LIMK2a (data not shown). Nevertheless, the possibility exists that the unique 'one and a half' LIM domain in LIMK2b may have created a binding motif distinct from those in the LIMK2a protein, thus disrupting the interaction of LIMK2b with LIM domain-interacting proteins or generating a new binding motif for a different set of proteins. This possibility is particularly appealing in terms of cell cycle regulation because the knockdown of LIMK2a and LIMK2b appear to have different outcomes in checkpoint regulation (Figure 5b ).
Similar and disparate roles of LIMK2a and LIMK2b in cell cycle regulation As p53 is one of the major factors controlling cell proliferation, we asked whether LIMK2b, as a p53 target, would act similarly to regulate cell growth. Indeed, LIMK2b and LIMK2a both inhibited colony formation (Figure 3a and Supplementary Figure S4) , suggesting that LIMK2 functions as a growth suppressor similar to many other p53-activated targets. The underlying cause of suppression by LIMK2 is not the arrest of cell growth, because we observed no marked change in the G1 or G2 phase in our transient or inducible expression assays. Instead, impaired cytokinesis was seen on induction of LIMK2b or LIMK2a expression in the Tet-Off HeLa cells (Figure 4 and Supplementary Figure S5 ). This may not be totally unexpected because the ectopic expression of Xenopus LIMKs (Xlimk1/2) in oocytes inhibits meiotic progression (Takahashi et al., 2001) . In addition, disruption of cofilin phosphorylation, which is normally transiently upregulated in the M-phase of the cell cycle (Amano et al., 2002) , frequently results in failure of cytokinesis (Gunsalus et al., 1995; Abe et al., 1996; Hotulainen et al., 2005) . These results suggest that proper modulation of cofilin phosphorylation is essential for successful cell division. It is possible that increased LIMK2b expression, similar to that on DNA damage, may lead to unscheduled upregulation of cofilin phosphorylation and inhibition of cytokinesis. This is supported by our data showing that cofilin phosphorylation is enhanced on LIMK2b induction in inducible LIMK2b cells (Figure 4d ) and in cells treated with DNA-damaging agents (Figure 6a ).
Despite similarities in the regulation of cofilin phosphorylation, LIMK2a and LIMK2b seem to be functionally distinct in checkpoint response after stress. Depletion of LIMK2b resulted in impaired G2/M arrest, whereas downregulation of LIMK2a had no apparent effect (Figure 5b ), suggesting that LIMK2b rather than LIMK2a of the LIMK2 locus is involved in stress-induced checkpoint control. Such disparity may simply be because LIMK2b, but not LIMK2a, is increased by stress, and with LIMK2b depletion, endogenous levels of LIMK2a may not be sufficient to conduct proper checkpoint control. Alternatively, LIMK2b may function distinctively because of its unique LIM domain. It was noted that, although equally active in vitro, LIMK2a and LIMK2b did distribute differently in cells (Figure 3c ). It is possible that by interacting with different proteins through their distinct N-termini, these two kinases may each participate in separate signaling networks.
How LIMK2b triggers the G2/M arrest is intriguing. As cofilin is the only physiological substrate known for LIMK2, we postulated that the G2/M arrest is accomplished by interfering with actin cytoskeleton reorganization and induction of stress fibers through phosphorylation of cofilin. This hypothesis is supported by data showing that overexpression of the cofilin S3D mutant and LIMK2b promoted DNA damage-induced G2/M arrest (Figures 5e and 6c) . If this were the case, one would expect that cofilin phosphorylation after DNA damage is mostly contributed by LIMK2b rather than by LIMK2a, a speculation corroborated by the knockdown experiment showing that LIMK2b depletion alone abolished DNA damage-induced cofilin phosphorylation (Figure 6b ). How stress fibers affect cell cycle progression is not entirely clear; however, emerging evidence suggests that they may be related. For example, cyclin D1, which is often amplified in tumors, inhibits ROCKII expression, and cyclin D1-deficient cells display increased stress fiber formation and reduced cell motility, which can be reversed by ROCK inhibition (Li et al., 2006) . Moreover, oncogenic RasV12 inhibits ROCK and uncouples Rho-GTP from stress fiber formation (Sahai et al., 2001; Lee and Helfman, 2004) . As cyclin D1 and RasV12 are growth promoters, one would expect that the formation of stress fibers may be an unfavorable event for cell cycle progression. Further investigation is needed to unravel the details of the p53-LIMK2b-cofilin axis in the checkpoint control pathway.
LIMK2b as a possible candidate tumor suppressor Cancer cells often acquire the property of migration to facilitate invasion and metastasis. In that regard, p53 regulates a plethora of genes involved in cell morphology and movement (Harms et al., 2004) . Loss of p53 leads to significant increases in cell motility (Guo et al., 2003; Gade´a et al., 2007) and cell spreading (Gade´a et al., 2002) . These effects are mediated largely through regulation of the Rho-GTPase family. In this report, we have established an additional link between p53 and the Rho signaling pathway through the identification of LIMK2b as a p53 target. Importantly, LIMK2b overexpression not only suppressed cell proliferation but also inhibited cell migration, and reduced LIMK2b expression was observed in some human cancers (thyroid and esophageal). These observations implicate a possible role of LIMK2b in negative regulation of tumor growth. Further investigation is warranted to establish this link and to determine its role against tumor formation.
Materials and methods

Antibodies
Antibodies purchased from Cell Signaling (Danvers, MA, USA) included anti-LIMK2 (8C11), anti-cofilin (#3312), antiphospho-cofilin (Ser3, #3311) and anti-phospho-Cdc2 (Tyr15, #9111). Those obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were anti-Cdc2 (sc-54), anti-cyclin B1 (sc-245), anti-GFP (SC-8334) and anti-Myc (sc-40). Anti-HA (HA.11), anti-actin (A2066) and anti-p21 (Ab-6) were purchased from Covance (Emeryville, CA, USA), SigmaAldrich (St Louis, MO, USA) and Calbiochem (San Diego, CA, USA), respectively. Bound primary antibodies were detected using horseradish peroxidase-conjugated goat antimouse or anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) and chemiluminescent reagents (Thermo Scientific, Waltham, MA, USA).
Separation of LIMK2a and LIMK2b by SDS-polyacrylamide gel electrophoresis
To separate LIMK2a and LIMK2b, equivalent amounts of total proteins were resolved on 8% sodium dodecyl sulfate polyacrylamide gel (12 Â 14 cm) by electrophoresis. Separation of LIMK2a and LIMK2b was attained when the two markers, 83 and 62 kD (prestained protein maker, #P7708L; New England Biolabs, Beverly, MA, USA), were roughly 2 cm apart.
Reverse transcription-PCR and quantitative PCR Total RNA prepared by TRIzol extraction (Invitrogen, Carlsbad, CA, USA) was reverse-transcribed using the SuperScript III reverse transcriptase (Invitrogen) and then amplified by PCR. The primer pairs used are listed in Supplementary  Table S1 .
Quantitative PCR was performed on TissueScan Cancer Survey Panels (CSRT101 and CSRT104; OriGene, Rockville, MD, USA) and TissueScan Gastroesophageal and Thyroid Cancer quantitative PCR Panels (HGRT501 and HTRT501; OriGene) using an ABI Prism 7500 thermocycler (Applied Biosystems Inc., Foster City, CA, USA). Primers used in this assay are listed in Supplementary Table S2. siRNA transfection All siRNAs were synthesized by Qiagen (Valencia, CA, USA). The sequences targeted by LIMK2a, LIMK2b and p53 siRNA were 5 0 -AGCCAGATATGGTACAGGA-3 0 , 5 0 -TTCACCTC CAGAGACCTGT-3 0 and 5 0 -GACTCCAGTGGTAATC TAC-3 0 , respectively. Transfection of siRNA was performed using oligofectamine (Invitrogen).
Flow cytometry
For FACS analysis, harvested cells were fixed in 100% ice-cold methanol for 24 h. Cells were then rehydrated in phosphatebuffered saline (PBS), treated with the propidium iodide staining solution (50 mg/ml propidium iodide and 0.5 mg/ml RNaseA in PBS) for 30 min at room temperature and analyzed using an FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). For phospho-histone H3 analysis, rehydrated cells were stained with phospho-histone H3 antibody (Ser10, #06-570; Upstate, Temecula, CA, USA) in Ab buffer (3% bovine serum albumin, 0.05% Tween-20 and 0.04% NaN 3 in PBS; 1:400 dilution) at 37 1C for 1 h. The cells were then rinsed with PBS and incubated with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG antibody (Jackson ImmunoResearch) in Ab buffer (1:500 dilution) at 37 1C for 30 min before propidium iodide staining and FACS analysis.
Time-lapse microscopy For time-lapse fluorescence microscopy, HeLa cells stably expressing GFP or LIMK2b-GFP were grown on 25-mm diameter glass coverslips and then synchronized with 65 ng/ml nocodazole for 18 h. After release into fresh medium, mitotic cells were imaged every 180 s for 7-11 h. Live-cell imaging of dividing cells was performed in a sealed chamber at 37 1C on an Axiovert 200 microscope (Carl Zeiss, Thornwood, NY, USA) with a Â 100 oil objective and differential interference contrast optics. Multidimensional acquisition was controlled by MetaMorph software (Molecular Devices, Downingtown, PA, USA).
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